HORIZON EUROPE
Europeo
Specific Challenge:Age-related macular degeneration (AMD) is a chronic disease and among the leading causes of blindness world-wide. Currently no effective treatments exist to address the major health problems of transition of intermediate AMD to late stage AMD with ‘geographic’ atrophy (GA). The development of novel pharmaceutical compounds is mainly limited by the lack of validated functional and structural clinical endpoints that can be used.
Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.
Scope:To develop clinical endpoints that are meaningful to patients and need to measure visual dysfunction beyond best-corrected visual acuity (BCVA), which is currently the only generally accepted functional clinical endpoint in retinal diseases.
Candidate clinical endpoints need to be systematically validated in adequate patient populations to be acceptable for regulatory authorities, health technology assessment (HTA) bodies, and payers.
Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.
Expected Impact:An extended toolbox of validated clinical en...
ver más
Specific Challenge:Age-related macular degeneration (AMD) is a chronic disease and among the leading causes of blindness world-wide. Currently no effective treatments exist to address the major health problems of transition of intermediate AMD to late stage AMD with ‘geographic’ atrophy (GA). The development of novel pharmaceutical compounds is mainly limited by the lack of validated functional and structural clinical endpoints that can be used.
Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.
Scope:To develop clinical endpoints that are meaningful to patients and need to measure visual dysfunction beyond best-corrected visual acuity (BCVA), which is currently the only generally accepted functional clinical endpoint in retinal diseases.
Candidate clinical endpoints need to be systematically validated in adequate patient populations to be acceptable for regulatory authorities, health technology assessment (HTA) bodies, and payers.
Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.
Expected Impact:An extended toolbox of validated clinical endpoints that are acceptable by regulators, HTA bodies/payers and patients will enable the development of therapeutics for dry AMD.
It will greatly facilitate future trial designs in dry AMD, in early clinical trials, which aim to show proof of new therapeutic concepts in patients, as well in late stage development targeting confirmation of efficacy and safety of novel therapeutic approaches in larger patient populations.
Please refer to the full topic text on the IMI2 Call 7 section of the IMI website.
ver menos
Características del consorcio
:
La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Características del Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Características de la financiación
You can access the description of the different topics in the Call topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
MI2 Coordination and Support Action (IMI2-CSA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
Please read carefully all provisions below before the preparation of your application.
You can access the description of the different topics in the Call topics text.
The budget breakdown for this Call is given at the end of the Call topics text, in the Call Conditions section (page 78), as well as the following information :
List of countries and applicable rules for funding
Eligibility and admissibility conditions
Evaluation criteria and procedure, scoring and threshold : described in the IMI Manual for Submission, Evaluation and Grant award
Indicative timetable for evaluation and grant agreement
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
MI2 Coordination and Support Action (IMI2-CSA):
Summary of the most relevant provisions for participating in IMI2 actions
Standard proposal template
Standard evaluation form
IMI2 Model Grant Agreement
Template for Essential Clinical Trials Information
Información adicional de la convocatoria
Otras ventajas
Ayudas Similares
| Abierta
| Próximamente
| Abierta